Literature DB >> 10961386

The biology of multiple myeloma.

J Drach1, H Kaufmann, E Urbauer, S Schreiber, J Ackermann, H Huber.   

Abstract

Multiple myeloma (MM) is a B-cell malignancy originating from pre-switched, follicle center B-lymphocytes which differentiate to plasma cells accumulating in the bone marrow. MM cells are characterized by a profound genetic instability resulting in a complex set of numerical and structural chromosomal abnormalities. Among these abnormalities, translocations involving 14q32, the immunoglobulin heavy-chain locus, are the most frequent aberrations, but translocation partners are remarkably heterogeneous. Chromosome 13q14 may harbor a critical tumor suppressor gene since MM patients with deletion of 13q14 experience short overall survival after conventional-dose and high-dose chemotherapy. Bone marrow stroma cells support growth and survival of MM cells, which in turn influence the bone marrow microenvironment. This is particularly evident by the markedly increased bone marrow vascularization observed in most patients with active MM.

Entities:  

Mesh:

Year:  2000        PMID: 10961386

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  5 in total

1.  Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells.

Authors:  Alicia Báez; José I Piruat; Teresa Caballero-Velázquez; Luís I Sánchez-Abarca; Isabel Álvarez-Laderas; M Victoria Barbado; Estefanía García-Guerrero; África Millán-Uclés; Jesús Martín-Sánchez; Mayte Medrano; José Antonio Pérez-Simón
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

2.  In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2.

Authors:  Ken Maes; Elizabeta Nemeth; G David Roodman; Alissa Huston; Flavia Esteve; Cesar Freytes; Natalie Callander; Eirini Katodritou; Lisa Tussing-Humphreys; Seth Rivera; Karin Vanderkerken; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2010-08-02       Impact factor: 22.113

3.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

Review 4.  The classification of lymphomas: a new beginning or the end of an era?

Authors:  A S Jack
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

Review 5.  The MYC oncogene - the grand orchestrator of cancer growth and immune evasion.

Authors:  Renumathy Dhanasekaran; Anja Deutzmann; Wadie D Mahauad-Fernandez; Aida S Hansen; Arvin M Gouw; Dean W Felsher
Journal:  Nat Rev Clin Oncol       Date:  2021-09-10       Impact factor: 66.675

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.